Back to top

Needham upgrades Amicus to Buy on reduced regulatory risk

Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target The FDA’s decision to no longer require a panel meeting for Travere’s (TXTX...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Amicus Therapeutics, Inc. (FOLD)